Examining how dupilumab affects immune cells in atopic dermatitis
Molecular Signatures of Cutaneous Dupilumab Response
This study is testing how the medication dupilumab affects immune cells in the skin of people with moderate to severe atopic dermatitis.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Drugs / interventions | dupilumab |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT05858619 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of dupilumab, an FDA-approved treatment for atopic dermatitis, on immune cells in skin lesions associated with the condition. It is a one-arm, open-label study that will enroll fifteen subjects with moderate to severe atopic dermatitis. Participants will undergo biopsy procedures to collect skin samples, which will then be analyzed through molecular profiling to understand the relationship between these profiles and the response to dupilumab treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with moderate to severe atopic dermatitis.
Not a fit: Patients who are pregnant, have known immunodeficiencies, or have parasitic infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help predict which patients will respond best to dupilumab, leading to more personalized treatment strategies for atopic dermatitis.
How similar studies have performed: Other studies have shown promising results in understanding treatment responses in atopic dermatitis, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18 years of age or older 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7 Exclusion Criteria: 1. Known pregnancy 2. Known immunodeficiencies 3. Known parasitic infection -
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Jeffrey Cheng, MD, PhD — University of California, San Francisco
- Study coordinator: Jeffrey Cheng, MD, PhD
- Email: rashes@ucsf.edu
- Phone: 415 575 0524
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.